The application significance of serum CYFRA21-1 change in therapeutic efficacy monitoring of advanced stage NSCLC

doi:10.3969/j.issn.1673-8640.2013.02.009

Abstract

Abstract: Objective　To investigate the significance of serum cytokeratin 19 fragment 21-1（CYFRA21-1） changes before and after chemotherapy in monitoring the therapeutic efficacy of advanced stage non small cell lung cancer（NSCLC）. Methods　The serum CYFRA21-1 levels of 66 patients with advanced stage NSCLC before and after chemotherapy and 30 healthy controls were measured by chemiluminescence immunoassay，and the change differences of serum CYFRA21-1 in the patients with different therapeutic efficacy were analyzed. Results　Compared to those in the controls，serum CYFRA21-1 levels were significantly higher than those in patients before the first-line chemotherapy（P＜0.05）. Furthermore，the serum CYFRA21-1 levels in patients with squamous cell lung carcinoma were higher than those with pulmonary adenocarcinoma（P＜0.05）. Compared to those before chemotherapy，serum CYFRA21-1 levels significantly decreased in release group after the first-line chemotherapy（P＜0.05）. However，compared to those before chemotherapy，serum CYFRA21-1 levels significantly decreased in invalid group and progress group（P＜0.05）. Conclusions　Serum CYFRA21-1 is exactly valuable in monitoring the pathogenetic condition and judging the chemotherapy efficacy of the patients with lung cancer.

Key words: Cytokeratin 19 fragment 21-1, Lung cancer, Chemotherapy, Prediction, Monitoring

ZHANG Guoming，MA Xiaobo，HU Liyi，ZANG Jialan，ZHANG Gaoming，XU Qinglei. The application significance of serum CYFRA21-1 change in therapeutic efficacy monitoring of advanced stage NSCLC[J]. , 2013, 28(2): 124-127.

References

[1]李玲，宋丽华，丁士超，等.癌胚抗原和细胞角蛋白19片段作为晚期非小细胞肺癌疗效评价指标的临床价值[J].中华肿瘤杂志，2011，32（11）：850-854.
[2]张国明，胡礼仪. 肺癌的新型标志Cytokaratin19的研究现状[J]. 牡丹江医学院学报，2011，32（3）:70-72.
[3]Ando S，Kimura H，Iwai N，et al. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer[J]. Anticancer Res，2001，21（4B）：3085-3092.
[4]Cabrera-Alarcon JL，Carrillo-Vico A，Santotoribio JD，et al. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer[J]. Clin Lab，2011，57（11-12）:1011-1014.
[5]冯晓鸿，孙业富，夏爱萍. 联合测定NSE、CYFRA21-1、PDGF-BB和D-D在肺癌患者中的临床意义[J]. 检验医学，2011，26（11）：741-745.
[6]Buccheri G，Torchio P，Ferrigno D，et al. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer：a study of tissue polypeptide antigen and cytokeratin 19 fragments[J]. Chest，2003，124（2）:622-632.
[7]Paone G，De Angelis G，Munno R，et al. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1[J]. Eur Respir J，1995，8（7）：1136-1140.
[8]Karnak D，Ulubay G，Kayacan O，et al. Evaluation of Cyfra21-1：a potential tumor marker for non-small cell lung carcinomas[J]. Lung，2001，179（1）:57-65.
[9]Nisman B，Biran H，Heching N，et al．Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer：association of marker changes after two chemotherapy cycles with different measures of chinical response and survival[J].Br J Cancer，2008，98（1）:77-79.
[10]Wang J，Zhang N，Li B，et al. Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC：a probable predictive factor for tumor response[J]. Tumour Biol，2011，32（4）:689-695.

[1]	JIN Weifeng, LI Dan, WANG Mengxia, PAN Nuoxuan, ZHANG Hong, LIN Ping. A risk prediction model for depressive disorders in children based on serum amino acids and cytokines [J]. Laboratory Medicine, 2025, 40(7): 666-672.
[2]	YU Xue, QI Aihong, LI Jinhui, QUAN Zhihui, LI Kui, QIU Yurong. Application role of an AI-patient based real time quality control intelligent monitoring platform for risk quality management of serum tumor markers [J]. Laboratory Medicine, 2025, 40(3): 264-270.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LU Xiuming, CHAI Baoying, CAO Yingqi, LIU Xin, YANG Lin. Roles of serum CA125，TRAP1 and HO-1 in efficacy evaluation of targeted therapy combined with chemotherapy for patients with advanced non-small cell lung cancer [J]. Laboratory Medicine, 2025, 40(10): 972-977.
[5]	WANG Yafei, ZHANG Zhenjun, SONG Changliang, YANG Qiong. Roles of Notch1 mRNA and Dickkopf-1 in assessing the therapeutic responsiveness of pembrolizumab in non-small cell lung cancer patients [J]. Laboratory Medicine, 2024, 39(7): 627-633.
[6]	WANG Xuexing, CHEN Chunmei, HE Yuan, CHU Jie, WEI Chunmei. Roles of thromboelastography and coagulation index in predicting venous thromboembolism in patients with tumors [J]. Laboratory Medicine, 2024, 39(5): 491-496.
[7]	DUAN Xuehan, WU Hua. Application of MALDI-TOF MS technology in clinical microbiological examination [J]. Laboratory Medicine, 2024, 39(4): 410-414.
[8]	SHEN Zhan, BIAN Xiaobo, HUANG Ying, WANG Siyang, SHEN Tingting, ZHANG Xian, SONG Yunxiao, XIE Lianhong. Stroke recurrence prediction model based on machine learning algorithms using routine blood test [J]. Laboratory Medicine, 2024, 39(12): 1190-1195.
[9]	CUI Xiaoyang, LIU Guodong, GUO Huijuan, LIAO Zhihong, LIU Yunhong, ZHANG Weifen, CHEN Zirao, WEI Xiaozhu. Roles of serum exosomal CEA，CA15-3 and CA125 in the differential diagnosis of non-small cell lung cancer and benign lung diseases [J]. Laboratory Medicine, 2024, 39(11): 1035-1041.
[10]	LEI Ming, ZHAI Li, WEI Ying, LIN Yichen, GUO Mengyue. Application of nomogram model based on clinical characteristics and serum tumor markers in differential diagnosis of benign and malignant lung lesions [J]. Laboratory Medicine, 2024, 39(10): 956-962.
[11]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[12]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[13]	WANG Huiying, TANG Yu, DONG Lili, WANG Jing. Role of Mycoplasma pneumoniae RNA determination in diagnosis and efficacy monitoring of pneumonia in children [J]. Laboratory Medicine, 2023, 38(9): 865-869.
[14]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[15]	YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523.